Effect of 1-Year Oral Administration of Dehydroepiandrosterone to 60- to 80-Year-Old Individuals on Muscle Function and Cross-sectional Area

Percheron, Gaëlle; Hogrel, Jean‐Yves; Denot-Ledunois, Sonjà; Fayet, Guy; Forette, Françoise; Baulieu, Étienne-Émile; Fardeau, Michel; Marini, Jean-François

doi:10.1001/archinte.163.6.720

Cited by 125 publications

(77 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatments lasted from 4 to 52 weeks and the number of patients in each study was relatively small (from 6 to 60 subjects), although most studies used randomized, double-blind designs. One study was performed in a large sample of men and women (n ¼ 280) (138). A total of eight studies indicated no effect of DHEA replacement on plasma lipids.…”

Section: Exogenous Dheamentioning

confidence: 99%

Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies

Tchernof

Labrie

2004

European Journal of Endocrinology

152

100

View full text Add to dashboard Cite

The age-related decline in serum dehydroepiandrosterone (DHEA) and its sulfated ester (DHEA-S) has suggested that a relative deficiency of these steroids may be causally related to the development of chronic diseases generally associated with aging, including insulin resistance, obesity, cardiovascular disease, cancer, reductions of the immune defense, depression and a general deterioration in the sensation of well-being. The numerous studies which have focused on the link between DHEA and cardiovascular disease have generally been inconsistent, generating much debate and controversy on this issue. The present article is an analysis of studies on the relationship between endogenous DHEA or DHEA-S, obesity and cardiovascular disease risk, as well as DHEA treatment studies. Elevated plasma levels of free DHEA are associated with reduced obesity in both men and women, and with smaller abdominal body fat accumulations in men. However, contradictory results have been reported regarding the relationships between the sulfate ester DHEA-S and adiposity. Age differences in the populations studied may have been a confounding factor in these associations. On the other hand, DHEA-S level is not a predictor of cardiovascular disease endpoints in women, and appears to be a relatively weak one in men. DHEA intervention studies suggest that the effects of DHEA on serum lipids are, at best, modest or non-significant. The uncertainty as to whether endogenous and exogenous DHEA should be considered cardioprotective is related to discrepancies in the literature on this topic. Several studies may have been plagued by methodological problems such as low power, unreliable analytical methods, confounding factors or other differences in the populations studied. As a consequence, the original reports demonstrating dramatic effects of either endogenous or exogenous DHEA on cardiovascular disease risk have never been replicated. We propose that the effects of DHEA on cardiovascular disease risk (either favorable or unfavorable) should be considered to be much more modest than previously believed.

show abstract

Section: Exogenous Dheamentioning

confidence: 99%

Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies

Tchernof

Labrie

2004

European Journal of Endocrinology

152

100

View full text Add to dashboard Cite

show abstract

“…This conclusion is supported by studies of stress related to sepsis and multiple trauma, in which low serum DHEAS was associated with poor survival in these patients (Beishuizen et al, 2002). The fact that DHEA can be readily supplemented (Baulieu et al, 2000) and has no recorded side-effects with long-term use (Percheron et al, 2003) suggests that this hormone may offer a potential intervention therapy to reduced mortality and morbidity associated with stress and trauma (Jarrar et al, 2001). …”

Section: Adrenal Antiglucocorticoids and Immunitymentioning

confidence: 99%

Stress responses and innate immunity: aging as a contributory factor

2004

View full text Add to dashboard Cite

SummaryEvolutionary pressure has selected individuals with traits that allow them to survive to reproduction, without consideration of the consequences for the post-child rearing years and old age. In the 21st century, society is populated increasingly by the elderly and with the falling birth rate and improved health care this trend is set to continue for the foreseeable future. To minimize the potential burden on health services one would hope that 'growing old gracefully' should also mean 'growing old healthily'. However, for too many the aging process is accompanied by increasing physical and mental frailty producing an elevated risk of physical and psychological stress in old age. Stress is a potent modulator of immune function, which in youth can be compensated for by the presence of an optimal immune response. In the elderly the immune response is blunted as a result of the decline in several components of the immune system (immune senescence) and a shifting to a chronic pro-inflammatory status (the so-called 'inflammaging' effect). We discuss here what is known of the effects of both stress and aging upon the innate immune system, focusing in particular upon the age-related alterations in the hypopituitary-adrenal axis. We propose a double hit model for age and stress in which the age-related increase in the cortisol/sulphated dehydroepiandrosterone ratio synergizes with elevated cortisol during stress to reduce immunity in the elderly significantly.

show abstract

“…In a study of men and women aged 50-65 years, (90) observed that supplementation with 100 mg of DHEA for 6 months increased lean body mass and decreased fat mass in both sexes, but increased muscle strength only moderately and only in men, and increased testosterone levels only in women. In a randomized placebocontrolled trial of 50 mg/day of DHEA supplementation for 1 year to men and women aged 60-80 years, (94) failed to reproduce Morales's results or detect an increase in lean mass, as indicated by measurements of body potassium.…”

Section: Anabolic Interventionsmentioning

confidence: 90%

Sarcopenia and Androgens: A Link between Pathology and Treatment

Basualto-Alarcón¹,

Varela²,

Durán³

et al. 2016

Clinical Nutrition and Aging

View full text Add to dashboard Cite

Sarcopenia, the age-related loss of skeletal muscle mass and function, is becoming more prevalent as the lifespan continues to increase in most populations. As sarcopenia is highly disabling, being associated with increased risk of dependence, falls, fractures, weakness, disability, and death, development of approaches to its prevention and treatment are required. Androgens are the main physiologic anabolic steroid hormones and normal testosterone levels are necessary for a range of developmental and biological processes, including maintenance of muscle mass. Testosterone concentrations decline as age increase, suggesting that low plasma testosterone levels can cause or accelerate muscle-and age-related diseases, as sarcopenia. Currently, there is increasing interest on the anabolic properties of testosterone for therapeutic use in muscle diseases including sarcopenia. However, the pathophysiological mechanisms underlying this muscle syndrome and its relationship with plasma level of androgens are not completely understood. This review discusses the recent findings regarding sarcopenia, the intrinsic, and extrinsic mechanisms involved in the onset and progression of this disease and the treatment approaches that have been developed based on testosterone deficiency and their implications.

show abstract

Effect of 1-Year Oral Administration of Dehydroepiandrosterone to 60- to 80-Year-Old Individuals on Muscle Function and Cross-sectional Area

Cited by 125 publications

References 32 publications

Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies

Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies

Stress responses and innate immunity: aging as a contributory factor

Sarcopenia and Androgens: A Link between Pathology and Treatment

Contact Info

Product

Resources

About